Myelopathy
Myelopathy refers to any neurological deficit related to the spinal cord. It arises from damage to the spinal cord, which can disrupt the transmission of nerve signals between the brain and the rest of the body. This damage can result from various causes, including inflammation, compression (e.g., from tumors or degenerative changes), infection, trauma, or genetic factors.
Biological Basis
At a biological level, myelopathy involves injury to the neurons or the myelin sheath that insulates nerve fibers within the spinal cord. Genetic predispositions and variations play a role in the susceptibility to certain forms of myelopathy. For instance, genome-wide association studies (GWAS) have been utilized to identify genetic associations with conditions such as HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). [1] Research has indicated the involvement of host genetic background, with specific HLA-DRB1 alleles carrying leucine in the antigen presentation groove domain being associated with HAM/TSP risk. [1]
Clinical Relevance
Clinically, myelopathy manifests with a range of symptoms depending on the location and extent of spinal cord damage. Common symptoms include gait disturbance, leg weakness, back pain, and bladder/bowel and sexual dysfunction. [1] Many forms of myelopathy are chronic and slowly progressive, potentially leading to an inability to walk over time. [1] Early diagnosis and intervention are crucial for managing symptoms and potentially slowing disease progression, although treatment options vary widely depending on the underlying cause.
Social Importance
Myelopathy significantly impacts the quality of life for affected individuals and their families, often leading to long-term disability and requiring extensive care. The prevalence of specific myelopathies can vary significantly across populations, highlighting the interplay of environmental and genetic factors. For example, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) shows differing prevalence rates, such as approximately 0.25% in the Japanese population compared to about 1.9% in the Caribbean population among HTLV-1-seropositive individuals. [1] Understanding these population-specific differences is vital for public health initiatives, targeted screening, and the development of effective treatments.
Methodological and Data Quality Constraints
The research primarily utilized electronic medical record (EMR) data collected from a single academic medical center in Taiwan. This single-center origin could introduce cohort-specific biases, potentially limiting the generalizability of findings to the broader Taiwanese population or other healthcare systems. Such reliance on a localized data source may not fully capture the genetic diversity or disease prevalence patterns across different regions or healthcare settings, impacting the representativeness of the study's conclusions. [2]
The use of EMRs, while valuable for longitudinal follow-up, presents inherent challenges in phenotype accuracy. Diagnostic recording in Taiwan, as elsewhere, is influenced by physician decisions and may include unconfirmed diagnoses, which can lead to false-positive results if not carefully managed. Although the study mitigated this by requiring three or more diagnoses for case inclusion, the presence of unrecorded comorbidities remains a concern, potentially leading to false-negative outcomes in both case and control groups. Furthermore, a hospital-centric database inherently lacks "subhealthy" individuals, meaning nearly all participants have at least one documented diagnosis, which could skew disease association analyses. [2]
Generalizability and Population Specificity
A significant limitation arises from the study's primary focus on the Taiwanese Han population, which, while valuable for understanding East Asian genetics, highlights the broader issue of underrepresentation of non-European populations in genome-wide association studies. Genetic risk factors are highly influenced by ancestry, and findings from one population may not directly translate to others. For instance, an observed effect size for a variant like rs6546932 in SELENOI showed a notable discrepancy between the Taiwanese Han and UK Biobank populations, emphasizing that population-specific genetic backgrounds necessitate tailored polygenic risk score (PRS) models. [2]
The strong emphasis on the East Asian population, specifically Southern Han Chinese, Han Chinese from Beijing, and Kinh individuals, restricts the immediate generalizability of the genetic associations and PRS models to individuals of other ancestries. While the study included principal component analysis (PCA) adjustments, the distinct genetic architecture of the Taiwanese Han population means that the identified variants and their effect sizes might differ substantially in European, African, or other Asian populations. This underscores the need for diverse cohorts to identify rare variants and ensure global applicability of genetic risk prediction. [2]
Complex Disease Etiology and Unaccounted Factors
The study acknowledges that most diseases, including myelopathy, are complex and arise from an interplay of multiple genetic and environmental factors, rather than being driven by single genes. While polygenic risk scores (PRSs) aim to summarize cumulative genetic effects and can incorporate environmental factors, the current models may not fully capture these intricate gene-environment interactions. This inherent complexity means that a portion of disease heritability, often referred to as missing heritability, may remain unexplained by purely genetic associations, particularly when environmental exposures are not comprehensively integrated into the analytical framework. [2]
Despite the extensive genetic data, the predictive power of the constructed PRS models for various diseases was generally modest, with Area Under the Curve (AUC) values around 0.6. This suggests that current genetic models, even when adjusted for basic confounders like age and sex, may not fully explain disease susceptibility or progression. The absence of significant contributions from principal components in predicting disease risk, beyond age and sex, further indicates remaining knowledge gaps regarding the full spectrum of genetic and non-genetic factors influencing disease outcomes. Future research would benefit from stricter, more comprehensive criteria that combine diagnosis, medication history, and laboratory test results to yield clearer and more robust outcomes. [2]
Variants
The CNTN1 (Contactin 1) gene plays a crucial role in the development and maintenance of the nervous system, particularly in the formation of myelin, the insulating sheath around nerve fibers that facilitates rapid signal transmission. As a cell adhesion molecule, CNTN1 is involved in cell-cell recognition and interactions, which are essential for neuronal migration, axon guidance, and synapse formation. Dysregulation of CNTN1 expression or function can therefore impact neuronal health and contribute to neurological disorders, including those affecting the spinal cord.
Implications of CNTN1 variants, such as rs7131902, in myelopathy stem from the gene's fundamental involvement in myelin biology. Myelopathy refers to any neurological deficit related to the spinal cord, often characterized by progressive weakness, sensory changes, and gait disturbances, frequently caused by demyelination or axonal damage. Genetic variations affecting CNTN1 could theoretically impair the proper assembly or maintenance of myelin, leading to vulnerability to spinal cord injury or neuroinflammation, and thus contributing to the development or progression of myelopathic conditions. . This specific nomenclature clarifies the disease's etiology, linking it directly to infection with the Human T-cell Lymphotropic Virus type 1 (HTLV-1), and describes its characteristic clinical syndrome, tropical spastic paraparesis, thereby distinguishing it from other forms of myelopathy. [1] This emphasizes the importance of etiological and syndromic specificity in the terminology of spinal cord disorders.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs7131902 | CNTN1 | myelopathy |
Diagnostic Frameworks and Operational Definitions
The operational definition and diagnosis of myelopathy in large-scale research studies rely on standardized diagnostic criteria and comprehensive patient data. Medical diagnoses are frequently established using PheCode criteria, which involve applying these criteria on at least three distinct occasions to ensure diagnostic reliability and minimize false positives. [2] For control groups, individuals are carefully selected based on the absence of PheCode-defined diseases. [2] This approach provides a robust framework for categorizing participants into case and control groups based on their phenotypic profiles.
These diagnostic classifications are derived from extensive patient records, including physician-documented Electronic Medical Records (EMRs) that detail patient demographics, laboratory results, medical procedures, and diagnostic codes. [2] The International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes serve as foundational data, often being converted into corresponding PheCodes for broader phenome-wide association studies. [2] The integration of detailed longitudinal follow-up data, spanning many years, further enhances diagnostic accuracy, particularly for chronic and progressive conditions like many forms of myelopathy, by allowing for the refinement of diagnoses over time. [2]
Classification Systems and Genetic Risk Assessment
Classification of myelopathy extends beyond clinical symptomatology to incorporate genetic predispositions, employing both categorical and dimensional approaches. In genetic studies, diseases are categorized into case and control groups based on established PheCode classifications. [2] Genome-wide association studies (GWAS) then identify genetic variants significantly associated with specific myelopathies, such as HTLV-1-associated myelopathy/tropical spastic paraparesis, by applying stringent statistical thresholds, typically a P value of less than 5 × 10−8, or after Bonferroni correction, as low as P < 2.02 × 10−4. [1] These studies contribute to a nosological understanding by identifying genetic factors that distinguish disease subtypes.
Polygenic Risk Scores (PRS) offer a dimensional classification approach, quantifying an individual's cumulative genetic susceptibility by aggregating the effects of multiple genetic variants. [2] While the predictive accuracy of PRS models, as measured by Area Under the Curve (AUC) values, may vary (often around 0.6 for many traits), their utility in risk stratification is significantly enhanced when combined with clinical features and adjusted for confounders like age and sex, sometimes achieving AUC values exceeding 0.8. [2] This integrated approach allows for a more nuanced classification, identifying individuals at higher genetic risk and contributing to a deeper understanding of the genetic architecture of myelopathy and its diverse forms.
Causes
Myelopathy refers to any neurological deficit related to the spinal cord. Its causes are diverse, encompassing viral infections, genetic predispositions, and complex interactions between an individual's genetic makeup and environmental factors. A prominent example is Human T-cell Leukemia Virus type 1 (HTLV-1)–associated myelopathy/tropical spastic paraparesis (HAM/TSP), a chronic and progressive form of myelopathy.
Viral Infection and Host Immune Response
Myelopathy, particularly HAM/TSP, is primarily caused by chronic infection with the HTLV-1 retrovirus. This virus leads to a slowly progressive meningomyelitis affecting both the white and gray matter of the central nervous system, resulting in characteristic symptoms such as gait disturbance, leg weakness, back pain, and bladder/bowel dysfunction. [1] The proviral load of HTLV-1, which represents the amount of viral genetic material within infected cells, is significantly associated with the risk of developing HAM/TSP, indicating that higher viral presence contributes to disease initiation and progression. [1] The persistent viral infection triggers a complex and often dysregulated host immune response, which is central to the inflammatory and degenerative processes observed in the spinal cord.
Genetic Predisposition and HLA Alleles
Host genetic factors play a substantial role in individual susceptibility to myelopathy, particularly in determining which HTLV-1-infected individuals develop HAM/TSP. Large-scale genome-wide association studies (GWAS) have identified specific HLA (Human Leukocyte Antigen) alleles as significant risk factors. [1] For instance, HLA-DRB1 alleles carrying leucine at position 7 within the antigen presentation groove domain are strongly associated with an increased risk of HAM/TSP. [1] Conversely, alleles carrying proline at this same position have been found to be protective. [1] These variations in HLA proteins influence how viral antigens are presented to the immune system, thereby modulating the T-cell response and contributing to the pathology of myelopathy.
Gene-Environment Interactions and Population Differences
The development of myelopathy, particularly HAM/TSP, exemplifies how genetic predisposition interacts with environmental triggers. While HTLV-1 infection is a necessary precursor, the host's genetic background significantly dictates the likelihood of developing the disease. [1] This critical interaction is evident in the differing prevalence rates of HAM/TSP among HTLV-1-seropositive populations; for example, the prevalence is approximately 0.25% in the Japanese population compared to about 1.9% in the Caribbean population. [1] Such ethnic and geographic disparities underscore the crucial interplay between viral exposure and specific host genetic variants, like those found in the HLA region, in modulating disease susceptibility and progression.
Biological Background
Myelopathy, specifically Human T-cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), is a debilitating neurological disorder characterized by chronic and progressive inflammation of the spinal cord. This condition primarily affects the white and gray matter of the central nervous system, leading to a range of symptoms that severely impact motor function and quality of life. The development and progression of myelopathy are influenced by a complex interplay of viral factors, host genetics, and the resulting immune responses within the affected tissues. [1]
Pathophysiology of Myelopathy
Myelopathy manifests as a slowly progressive meningomyelitis, which is an inflammation of both the spinal cord and its surrounding membranes. This inflammatory process in the central nervous system (CNS) results in damage to the white matter, responsible for transmitting signals throughout the brain and body, and the gray matter, which plays a crucial role in processing information. [1] Clinically, this tissue damage leads to hallmark symptoms such as gait disturbance, progressive leg weakness, and chronic back pain. Over time, individuals often experience bladder, bowel, and sexual dysfunction, eventually culminating in an inability to walk, reflecting the severe disruption of homeostatic functions within the spinal cord. [1]
Genetic Susceptibility and Immune Response
Genetic factors play a significant role in determining an individual's susceptibility to myelopathy, particularly in the context of HTLV-1 infection. The human leukocyte antigen (HLA) gene complex, a critical component of the immune system, has been strongly implicated. [1] Specifically, certain HLA-DRB1 alleles carrying a leucine residue at position DRB1-GB-7 within the antigen presentation groove domain are associated with an increased risk of developing HAM/TSP, with an odds ratio of 2.11. [1] Conversely, a proline residue at the same DRB1-GB-7 position is associated with a protective effect, reducing the risk of disease. [1] These amino acid variations in the HLA-DRB1 protein directly influence its ability to bind and present viral peptides to T cells, thereby shaping the host's immune response to HTLV-1 and impacting disease progression. [1] Other HLA alleles, such as HLA-A*26, HLA-B*4002, HLA-B*4006, and HLA-B*4801, are known to affect the recognition of HTLV-1 Tax protein epitopes, influencing the generation of cytotoxic T lymphocytes and potentially contributing to viral persistence or immune-mediated damage. [3]
Viral Factors and Disease Progression
The Human T-cell leukemia virus type 1 (HTLV-1) is the primary etiological agent for HAM/TSP. Infection with HTLV-1 is a prerequisite for developing the myelopathy, although only a subset of infected individuals progress to clinical disease. [1] A critical factor influencing the risk of developing HAM/TSP is the HTLV-1 proviral load, which refers to the amount of viral DNA integrated into the host's genome. [1] Higher proviral loads are significantly associated with an increased risk of disease, suggesting that the extent of viral presence and replication directly contributes to the severity of the immune response and subsequent neurological damage. [1] This highlights a key pathophysiological process where ongoing viral activity likely drives the chronic inflammation and demyelination characteristic of myelopathy.
Tissue-Level Manifestations in the Central Nervous System
Myelopathy specifically targets the central nervous system, with the spinal cord being the primary site of pathology. The inflammatory processes involve both the white matter, rich in myelinated nerve fibers essential for rapid signal transmission, and the gray matter, which contains neuronal cell bodies and synapses critical for neural processing. [1] This widespread involvement across different spinal cord tissues leads to a complex array of neurological deficits. The damage to these vital structures disrupts the coordinated functioning of motor and sensory pathways, explaining the progressive loss of motor control, sensory disturbances, and autonomic dysfunctions observed in individuals with myelopathy. [1]
Genetic Predisposition and Immune Recognition
The development of myelopathy, particularly Human T cell leukemia virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP), is significantly influenced by host genetic factors that modulate immune responses. Genome-wide association studies have identified associations between specific HLA-DRB1 alleles and HAM/TSP risk, highlighting the critical role of immune regulatory mechanisms. [1] For instance, HLA-DRB1 alleles carrying leucine at the antigen presentation groove domain, specifically at position DRB1-GB-7, are strongly associated with susceptibility to HAM/TSP. [1] This amino acid residue is structurally located within the beta sheet of the peptide-binding grooves of the HLA-DR protein, indicating its direct involvement in antigen presentation to T cells and subsequent activation of intracellular signaling cascades that dictate the immune response. [1] The presence of such specific amino acid residues, like DRB1-GB-7-Leu, can lead to altered immune recognition of viral antigens, potentially resulting in dysregulated immune activation or ineffective viral clearance, thereby contributing to disease pathogenesis. [1]
Viral Influence and Cellular Dysregulation
The presence and activity of the Human T cell leukemia virus type 1 (HTLV-1) itself represent a primary pathway leading to myelopathy. A high HTLV-1 proviral load is a significant risk factor for developing HAM/TSP, suggesting a direct link between viral burden and disease onset and progression. [1] The virus's integration into the host genome and subsequent expression of viral proteins can trigger chronic inflammation and cellular dysregulation within the central nervous system. These viral-host interactions can initiate various intracellular signaling cascades, potentially leading to persistent immune cell activation and the release of pro-inflammatory mediators that damage neural tissue. [1] The chronic nature of HAM/TSP, characterized by slowly progressive meningomyelitis affecting both white and gray matter, underscores a sustained interplay between viral factors and host cellular responses that ultimately leads to neurological impairment. [1]
Molecular Mechanisms of Pathological Progression
The convergence of genetic susceptibility and viral persistence drives the pathological progression observed in myelopathy. Dysregulation in immune recognition, mediated by specific HLA alleles, along with a high HTLV-1 proviral load, contributes to an aberrant inflammatory response within the spinal cord. [1] This sustained neuroinflammation leads to the chronic and slowly progressive meningomyelitis characteristic of HAM/TSP, causing demyelination and neuronal damage in the white and gray matter of the central nervous system. [1] The ongoing damage manifests clinically as gait disturbance, leg weakness, back pain, bladder/bowel and sexual dysfunction, eventually leading to an inability to walk, reflecting the emergent properties of complex pathway crosstalk and network interactions within the nervous and immune systems. [1] The varied prevalence of HAM/TSP among different ethnicities, despite HTLV-1 seropositivity, further emphasizes the intricate systems-level integration of host genetic background and viral factors in shaping disease progression. [1]
Large-Scale Cohort Studies and Longitudinal Health Records
Population-level investigations into complex diseases, including myelopathy, often leverage large-scale cohort studies and biobanks that integrate extensive clinical and genetic data. The HiGenome cohort, comprising 323,397 participants of East Asian ancestry in Taiwan, serves as a robust example, utilizing electronic medical records (EMRs) collected from 2003 to 2021. [2] This cohort offers up to 19 years of longitudinal follow-up, with a significant proportion of participants (65.3% for >5 years, 46.3% for >10 years) providing a deep temporal perspective on disease progression and health outcomes. [2] Such detailed, physician-documented EMRs, as opposed to self-reported data, enhance diagnostic accuracy for chronic and progressive conditions, allowing for refined disease classification over multiple clinical visits. [2]
The comprehensive nature of cohorts like HiGenome, which includes individuals ranging from 0 to 111 years with a male-to-female ratio of 45.3:54.7, allows for the study of diverse demographic factors and their association with various health traits. [2] These large datasets facilitate extensive genomic analyses, such as genome-wide association studies (GWASs) and phenome-wide association studies (PheWASs), to uncover genetic architectures and polygenic risk scores (PRSs) for a wide array of diseases. [2] While specific findings for myelopathy within the HiGenome cohort are not detailed in the provided research, the methodology underscores the power of such resources in identifying genetic and environmental contributors to complex neurological disorders through long-term observation and precise clinical phenotyping. [2]
Cross-Population Genetic and Epidemiological Associations
Population studies are critical for understanding how genetic predispositions and environmental factors contribute to myelopathy across different ethnic and geographic groups. A genome-wide association study specifically investigated HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) within the Japanese population, aiming to identify genetic variants linked to the condition. [1] Such studies highlight the importance of population-specific genetic backgrounds in disease susceptibility, as genetic associations can vary significantly between ancestries.
Beyond specific disease-gene associations, broader cross-population comparisons reveal variations in genetic architecture. For instance, studies have identified differences in the proportion of certain human leukocyte antigen (HLA) subtypes between Southern Han Chinese individuals and Han Chinese individuals from Beijing, including HLA-A*11:01 and HLA-B*40:01. [2] While these findings are not directly related to myelopathy in the provided context, they illustrate how genetic variations, even within broadly defined ethnic groups, can influence disease risk and underscore the necessity of diverse population cohorts for comprehensive genetic research. The integration of genotypic data from custom SNP arrays and whole-genome sequencing, enhanced by imputation, allows for the exploration of nearly 14 million reference points, providing a high-resolution view of population-specific genetic landscapes. [2]
Methodological Rigor and Generalizability Considerations
The design and execution of population studies are paramount for the reliability and generalizability of their findings. The HiGenome cohort, for example, employed rigorous methodologies, including the use of International Classification of Diseases (ICD-9-CM and ICD-10-CM) codes and PheCode criteria applied on at least three distinct occasions to establish robust disease diagnoses. [2] This approach ensures high data accuracy and reduces misclassification, particularly vital for chronic conditions that evolve over time. Case-control study designs within these cohorts involve careful stratification by age and sex, with logistic regression models adjusted for confounders like age, sex, and principal components to minimize bias and account for population structure. [2]
However, the generalizability of findings from specific populations, such as the Taiwanese Han or Japanese populations, requires careful consideration. While deeply integrated clinical records and extensive longitudinal follow-up in cohorts like HiGenome offer strong internal validity, their direct applicability to other ethnic groups or geographical regions may vary due to differences in genetic backgrounds, environmental exposures, and healthcare systems. [2] The stringent statistical thresholds (e.g., P < 5 × 10−8 for GWAS, P < 2.02 × 10−4 after Bonferroni correction for specific analyses in myelopathy studies) are crucial for identifying significant associations while minimizing false positives, yet these findings must be validated in diverse populations to ensure broader relevance. [2]
Frequently Asked Questions About Myelopathy
These questions address the most important and specific aspects of myelopathy based on current genetic research.
1. Will my kids definitely get myelopathy if I have it?
It depends on the specific cause of your myelopathy. While genetic factors can play a role in susceptibility, many forms are not directly inherited in a simple way. Most diseases, including myelopathy, are complex, involving an interplay of multiple genes and environmental factors, so it's not a certainty. Early diagnosis and intervention are important for management, regardless of genetic predisposition.
2. Does my family's background affect my myelopathy risk?
Yes, your genetic background and ancestry can definitely influence your risk. For example, conditions like HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) show different prevalence rates in various populations, like Japanese versus Caribbean individuals, even among those exposed to the virus. This highlights how your specific genetic makeup, including certain immune system genes, can make you more or less susceptible.
3. If I have myelopathy, will I eventually stop walking?
Not necessarily, but it's a significant concern for many. Many forms of myelopathy are chronic and slowly progressive, and some can indeed lead to an inability to walk over time. However, early diagnosis and intervention are crucial for managing symptoms and potentially slowing down disease progression, so outcomes can vary widely depending on the underlying cause and treatment.
4. Why do some people get myelopathy while others stay healthy?
Myelopathy is a complex condition with various causes, including inflammation, trauma, infection, and genetic factors. Even with similar exposures, genetic predispositions play a role in how susceptible someone is. For instance, specific variations in genes like HLA-DRB1 can increase the risk for certain types of myelopathy in some individuals, while others with different genetic profiles might be more resilient.
5. Can I avoid myelopathy even if it runs in my family?
It's complicated, as genetic risk factors are significant, but they aren't the only piece of the puzzle. Myelopathy often results from a combination of genetic and environmental factors. While you can't change your genes, managing environmental exposures, treating infections, and addressing other risk factors can potentially influence your overall risk or the severity of the condition.
6. Can a DNA test predict if I'll get myelopathy?
For some specific types of myelopathy, DNA tests can identify genetic markers associated with increased risk, like certain HLA-DRB1 alleles for HAM/TSP. However, myelopathy is a complex disease, and most genetic tests provide only a risk factor, not a definitive prediction. Many factors beyond genetics, including environmental influences, contribute to whether someone develops the condition.
7. Could my leg weakness and back pain be myelopathy?
It's possible, as leg weakness and back pain are common symptoms of myelopathy, along with gait disturbance and bladder or bowel issues. However, these symptoms can also be caused by many other conditions. If you're experiencing these issues, it's very important to see a doctor for a proper diagnosis, as early intervention is crucial for myelopathy management.
8. Does where I live change my risk for myelopathy?
Yes, where you live can influence your risk, especially due to varying environmental factors and the prevalence of certain infections. For example, HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) shows significantly different prevalence rates in populations like the Japanese compared to Caribbean individuals. This highlights how regional factors and population-specific genetic backgrounds interact to affect disease risk.
9. Is there anything I can do daily to lower my risk?
While genetic factors are largely beyond your control, addressing modifiable risk factors can be helpful. Myelopathy can stem from inflammation, infection, trauma, or compression. Focusing on general health, preventing injuries, and managing underlying conditions that could lead to spinal cord damage can contribute to overall neurological well-being, though it's not a guaranteed prevention.
10. Why does myelopathy affect people so differently?
The severity and specific symptoms of myelopathy depend heavily on the location and extent of spinal cord damage, as well as the underlying cause. Genetic factors also play a role in individual susceptibility and how the body responds to damage. This complex interplay means that even with similar causes, two people might experience very different disease progression and symptoms.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Penova, M et al. "Genome wide association study of HTLV-1-associated myelopathy/tropical spastic paraparesis in the Japanese population." Proc Natl Acad Sci U S A, 2021.
[2] Liu, T. Y., et al. "Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population." Science Advances, vol. 11, 4 June 2025, eadt0539.
[3] Yashiki, S., et al. "HLA-A26, HLA-B4002, HLA-B4006, and HLA-B4801 alleles predispose to adult T cell leukemia: The limited recognition of HTLV type 1 tax peptide anchor motifs and epitopes to generate anti-HTLV type 1 tax CD8(+) cytotoxic T lymphocytes." AIDS Res Hum Retroviruses, vol. 17, no. 11, 2001, pp. 1047-61.